Skip to main content
Press Release Published: Apr 4, 2024

Oversight Committee to Hold Hearing with FDA Commissioner

WASHINGTON—The House Committee on Oversight and Accountability will hold a hearing tiled “Oversight of the Food and Drug Administration.” The hearing will examine the Oversight Committee’s ongoing investigations into the Food and Drug Administration’s (FDA) response to several issues, including the infant formula crisis and food safety, drug shortages, facility inspections, hemp regulation, regulation of tobacco and nicotine products, and over-the-counter decongestants.

“The Oversight Committee has highlighted several crises occurring on the FDA’s watch which have negatively impacted the lives and health of American people and families. From a botched response to a nationwide infant formula crisis, failure to regulate safe tobacco products, failure to prepare for and address critical drug shortages, and more, we have identified how dysfunction at the FDA could be worsening many of these preventable crises. We will hold the Commissioner accountable for what the FDA is doing to address ongoing crises, how they are conducting inspections to prevent nationwide crises in the future, and how they intend to ensure the FDA is first and foremost protecting American consumers. Subcommittee Chairwoman McClain has been at the forefront of the Oversight Committee’s efforts to bring transparency to the FDA and we look forward to continuing that work at this hearing,” said Oversight Committee Chairman James Comer (R-Ky.).

WHAT: Hearing tiled “Oversight of the Food and Drug Administration”

DATE: Thursday, April 11, 2024

TIME: 1:00 PM ET

WITNESS: FDA Commissioner Dr. Robert Califf

WATCH: The hearing will be open to the public and press and will be livestreamed online at https://oversight.house.gov/.

Read More:

Comer Probes FDA’s Tobacco and Nicotine Regulatory Programs Riddled with Uncertainty

McClain Probes FDA’s Response to Common Over-the-Counter Decongestant Deemed Ineffective

Hearing Wrap Up: FDA’s Failure to Regulate CBD Threatens Consumer Access to Safe Products

Comer, McClain Open Probe into FDA’s Response to National Drug Shortage

Hearing Wrap Up: Former FDA Official: Infant Formula Crisis Was “A Preventable Tragedy”

Comer & McClain Press FDA on Infant Formula Crisis Response

Hearing Wrap Up: FDA’s Food Safety Director Acknowledges ‘Less Than Ideal’ Slow Response to Formula Crisis